Welcome to our dedicated page for Alps Group news (Ticker: ALPS), a resource for investors and traders seeking the latest updates and insights on Alps Group stock.
Alps Group Inc operates as the public parent of Alps Life Sciences Inc., an integrated biotechnology research and healthcare platform focused on predictive, preventive, and precision medicine. The company became the surviving publicly traded entity after a completed business combination with Globalink Investment Inc., with Alps Holdco becoming a wholly owned subsidiary.
Recurring Alps Group news centers on clinical publications and pipeline activity involving autologous Natural Killer cell infusions produced with an in-house culture protocol, CELESOME(+) exosome-related development, and advanced-therapy healthcare services. Corporate updates also cover board composition, audit and compensation committee roles, finance leadership, governance oversight, and capital markets-related public-company matters.
Alps Group (Nasdaq:ALPS) received a Nasdaq notice on May 15, 2026 for not meeting the $1.00 minimum bid price requirement after 30 consecutive business days below this level.
The notice has no immediate impact on listing, trading, operations, or financial condition. Alps has 180 days, until November 11, 2026, to regain compliance and may qualify for an additional 180 days, but faces potential delisting if the deficiency is not cured.
Alps Group (NASDAQ: ALPS) appointed Mr. Hee H. Lee to its Board of Directors effective April 17, 2026, increasing the Board from five to six directors. Mr. Lee is independent under Nasdaq rules and will join the Audit and Compensation Committees.
Mr. Lee brings over 35 years of public accounting and advisory experience, including service as a partner at Ernst & Young and leadership of the Americas FAAS practice, strengthening governance and capital markets oversight for the public company.
Alps Group (NASDAQ:ALPS) published a peer-reviewed case series (Feb 2026) reporting safety and tolerability data from nine patients who received autologous NK cell infusions produced with its in-house culture protocol.
The study (NMRR ID 25-00333-MUM) and Malaysian patent application PI2025002484 describe an antibody-free, cost-efficient method for large-scale NK cell production and aim to support future clinical trials.
Alps Group (NASDAQ:ALPS) announced potential expansion of its exosome pipeline beyond CELESOME(+) following publication of a peer‑reviewed retrospective clinical case series on nebulized hUCMSC‑derived exosomes in patients with asthma and/or COPD.
The published series reports observed improvements in pulmonary function, stable inflammatory markers, and no significant adverse effects after weekly 30‑minute nebulized dosing for five weeks (1 ml exosome solution mixed with 5 ml saline).
Alps Group (NASDAQ: ALPS) appointed Cheing Lye-Ping (Penny) as Chief Financial Officer, effective January 5, 2026. Ms. Cheing will lead financial strategy, budgeting, planning and analysis, audit, tax compliance, risk management, accounting, and treasury across Alps Group and subsidiaries. She brings over 30 years of finance and accounting experience, including CFO and CEO roles in property development and investment firms, and early-career audit experience at Arthur Andersen. Ms. Cheing holds a Bachelor in Accountancy, an MBA, is a Chartered Accountant with the Malaysian Institute of Accountants, and a Fellow of CPA Australia.
Alps Group Inc (NASDAQ: ALPS) completed its business combination with Globalink Investment Inc. and began trading on Nasdaq on October 31, 2025, with warrants trading OTC under ALPWF. The combined company has an estimated enterprise value of ~US$1.6 billion and will be headquartered in Kuala Lumpur, Malaysia.
Leadership carries forward from Alps Holdco, with Dr. Tham Seng Kong serving as CEO and chairman. A concurrent PIPE raised approximately US$3,107,875 for roughly 310,788 ordinary shares to support growth and working capital. The transaction used a two-step merger (Redomestication Merger and Acquisition Merger) and was approved by Globalink stockholders on October 7, 2025.
Summary not available.
Summary not available.
Summary not available.
Summary not available.